These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 16218172

  • 1. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.
    Sheldon J, Camino N, Rodés B, Bartholomeusz A, Kuiper M, Tacke F, Núñez M, Mauss S, Lutz T, Klausen G, Locarnini S, Soriano V.
    Antivir Ther; 2005; 10(6):727-34. PubMed ID: 16218172
    [Abstract] [Full Text] [Related]

  • 2. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
    Audsley J, Arrifin N, Yuen LK, Ayres A, Crowe SM, Bartholomeusz A, Locarnini SA, Mijch A, Lewin SR, Sasadeusz J.
    HIV Med; 2009 Apr; 10(4):229-35. PubMed ID: 19178592
    [Abstract] [Full Text] [Related]

  • 3. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
    Quiros-Roldan E, Calabresi A, Lapadula G, Tirelli V, Costarelli S, Cologni G, Zaltron S, Puoti M, Carosi G, Torti C.
    Antivir Ther; 2008 Apr; 13(3):341-8. PubMed ID: 18572746
    [Abstract] [Full Text] [Related]

  • 4. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
    Alvarez-Uria G, Ratcliffe L, Vilar J.
    HIV Med; 2009 May; 10(5):269-73. PubMed ID: 19210695
    [Abstract] [Full Text] [Related]

  • 5. High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B.
    Mendes-Correa MC, Pinho JR, Locarnini S, Yuen L, Sitnik R, Santana RA, Gomes-Gouvêa MS, Leite OM, Martins LG, Silva MH, Gianini RJ, Uip DE.
    J Med Virol; 2010 Sep; 82(9):1481-8. PubMed ID: 20648600
    [Abstract] [Full Text] [Related]

  • 6. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
    Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C, Rozenbaum W, Le Teuff G, Trylesinski A, Piketty C, TECOVIR Study Group.
    Hepatology; 2006 Mar; 43(3):548-55. PubMed ID: 16496322
    [Abstract] [Full Text] [Related]

  • 7. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V.
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [Abstract] [Full Text] [Related]

  • 8. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains.
    Amini-Bavil-Olyaee S, Herbers U, Sheldon J, Luedde T, Trautwein C, Tacke F.
    Hepatology; 2009 Apr; 49(4):1158-65. PubMed ID: 19263474
    [Abstract] [Full Text] [Related]

  • 9. The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
    Zhu Y, Curtis M, Borroto-Esoda K.
    Antivir Chem Chemother; 2011 Aug 23; 22(1):13-22. PubMed ID: 21860069
    [Abstract] [Full Text] [Related]

  • 10. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
    Jain MK, Comanor L, White C, Kipnis P, Elkin C, Leung K, Ocampo A, Attar N, Keiser P, Lee WM.
    J Viral Hepat; 2007 Mar 23; 14(3):176-82. PubMed ID: 17305883
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
    Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, Lu B, Cheng AK, 903 Study Team, 907 Study Team.
    J Infect Dis; 2004 Apr 01; 189(7):1185-92. PubMed ID: 15031786
    [Abstract] [Full Text] [Related]

  • 12. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
    Stephan C, Berger A, Carlebach A, Lutz T, Bickel M, Klauke S, Staszewski S, Stuermer M.
    J Antimicrob Chemother; 2005 Dec 01; 56(6):1087-93. PubMed ID: 16269552
    [Abstract] [Full Text] [Related]

  • 13. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
    Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, von Boemmel F, Hoffmann C, Rockstroh J, Stoehr A, Wolf E, Soriano V, Berger F, Berg T, Carlebach A, Schwarze-Zander C, Schürmann D, Jaeger H, Mauss S.
    AIDS; 2006 Oct 03; 20(15):1951-4. PubMed ID: 16988516
    [Abstract] [Full Text] [Related]

  • 14. Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.
    Amini-Bavil-Olyaee S, Sheldon J, Lutz T, Trautwein C, Tacke F.
    AIDS; 2009 Jan 14; 23(2):268-72. PubMed ID: 19098499
    [Abstract] [Full Text] [Related]

  • 15. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.
    van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Möller B, Feucht HH, Wiedenmann B, Berg T.
    Hepatology; 2006 Aug 14; 44(2):318-25. PubMed ID: 16871563
    [Abstract] [Full Text] [Related]

  • 16. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B, Neau D, Boucher S, Lavignolle-Aurillac V, Schrive MH, Recordon-Pinson P, Ragnaud JM, Fleury H.
    Antivir Ther; 2006 Aug 14; 11(6):827-30. PubMed ID: 17310827
    [Abstract] [Full Text] [Related]

  • 17. Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.
    Matthews GV, Cooper DA, Dore GJ.
    Antivir Ther; 2007 Aug 14; 12(1):119-22. PubMed ID: 17503756
    [Abstract] [Full Text] [Related]

  • 18. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.
    van der Eijk AA, Hansen BE, Niesters HG, Janssen HL, van de Ende M, Schalm SW, de Man RA.
    J Viral Hepat; 2005 Jul 14; 12(4):364-72. PubMed ID: 15985006
    [Abstract] [Full Text] [Related]

  • 19. Detection of hepatitis B virus variants in HBV monoinfected and HBV/HIV coinfected Iranian patients under lamivudine treatment.
    Aghasadeghi MR, Bahramali G, Sadat SM, Farahani A, Mohraz M, Davar Siadat S, Mostafavi E, Memarnejadian A, Ardestani MS, Vahabpour R, Saraji AA, Delbaz SA.
    Curr HIV Res; 2011 Jun 14; 9(4):263-9. PubMed ID: 21671883
    [Abstract] [Full Text] [Related]

  • 20. Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patients.
    de Vries-Sluijs TE, van der Eijk AA, Hansen BE, Osterhaus AD, de Man RA, van der Ende ME.
    J Clin Virol; 2006 May 14; 36(1):60-3. PubMed ID: 16418013
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.